FDA approves Celcuity's Revtorpyk for PIK3CA wild-type breast cancer after CDK4/6 failure
Gedatolisib plus fulvestrant and palbociclib reached 9.3 months median progression-free survival against 2.0 on fulvestrant alone.
FDA approves Arvinas and Pfizer's Veppanu, a PROTAC protein degrader, in ESR1-mutated breast cancer
Vepdegestrant more than doubled median progression-free survival against fulvestrant in ESR1-mutated advanced breast cancer, at 5.0 months against 2.1.